Development of markers of prostate cancer metastasis: Review and perspective

Urologic Oncology

Volumn 5, Issue 5, 2000, Pages 217-223

  Christiano, Arthur P ^a   Yoshida, Barbara A ^a   Dubauskas, Zita ^a   Sokoloff, Mitchell ^a   Rinker Schaeffer, Carrie W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dormancy; Metastasis suppressor genes; Prostate cancer

Indexed keywords

CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; LABORATORY DIAGNOSIS; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0033833972     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00070-3     Document Type: Review

References (62)

1. Landis S.H.et al. Cancer statistics, 1999. CA Cancer J Clin. 49(1):1999;8-31. [see comments].
2. Walsh P. The natural history of localized prostate cancer. Walsh P.C., Vaughn E.D., Wein A.J. Campbell's Urology. 1998;2539-2546 W.B. Saunders Company, Philadelphia.
3. Carter H., Partin A.W. Diagnosis and staging of prostate cancer. Walsh P.C., Vaughn E.D., Wein A.J. Campbell's Urology. 1998;2519-2538 W.B. Saunders Company, Philadelphia.
4. Isaacs J.T. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol. 150(5):1997;1511-1521.
5. Voges G.E.et al. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer. 69(2):1992;520-526.
6. Partin A.W.et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 150(1):1993;110-114. [see comments].
7. Pound C.R.et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 24(2):1997;395-406.
8. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen. A decade of discovery - what we have learned and where we are going J Urol. 162(2):1999;293-306.
9. Gomella L.G., Raj G.V., Moreno J.G. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol. 158(2):1997;326-337. [see comments].
10. Poste G., Fidler I.J. The pathogenesis of cancer metastasis. Nature. 283(5743):1980;139-146.
11. Welch D.R., Rinker-Schaeffer C.W. What defines a useful marker of metastasis in human cancer? J Natl Cancer Inst. 91(16):1999;1351-1353.
12. MacDonald N.J., Steeg P.S. Molecular basis of tumour metastasis. Cancer Surv. 16:1993;175-199.
13. Steeg P.S.et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 80(3):1988;200-204.
14. Yang X.et al. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett. 119(2):1997;149-155.
15. Dong J.T.et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 56(19):1996;4387-4390.
16. Fidler I.J. Review. Biologic heterogeneity of cancer metastases Breast Cancer Res Treat. 9(1):1987;17-26.
17. Folkman J. Angiogenesis and angiogenesis inhibition. An overview Exs. 79:1997;1-8.
18. Holash J.et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284(5422):1999;1994-1998.
19. Fidler I.J. Critical factors in the biology of human cancer metastasis. Twenty-eighth G.H.A. Clowes memorial award lecture Cancer Res. 50(19):1990;6130-6138.
20. Matrisian L.M.et al. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci. 302(3):1991;157-162.
21. Yang M.et al. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 59(4):1999;781-786.
22. Fisher E.R., Fisher B. Recent observations on concepts of metastasis. Arch Pathol. 83(4):1967;321-324.
23. Greene G.F.et al. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol. 150(5):1997;1571-1582.
24. Pantel K., Cote R.J., Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 91(13):1999;1113-1124.
25. Yoshida B.A.et al. Prostate cancer metastasis-suppressor genes. A current perspective In Vivo. 12(1):1998;49-58.
26. Isaacs J.T.et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate. 9(3):1986;261-281.
27. Chekmareva M.A.et al. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res. 58(21):1998;4963-4969.
28. Dong J.T.et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268(5212):1995;884-886. [see comments].
29. Ichikawa T.et al. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res. 52(12):1992;3486-3490.
30. Ichikawa T.et al. Metastasis suppressor genes for prostate cancer. Prostate Suppl. 6:1996;31-35.
31. Ichikawa T.et al. Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res. 54(9):1994;2299-2302.
32. Nihei N.et al. Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Genes Chromosomes Cancer. 14(2):1995;112-119.
33. Nihei N.et al. Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7. Genes Chromosomes Cancer. 24(1):1999;1-8.
34. Luu H.H.et al. Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Res. 58(16):1998;3561-3565.
35. Mashimo T.et al. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res. 58(20):1998;4572-4576.
36. Chekmareva M.A.et al. Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate. 33(4):1997;271-280.
37. Guo X.et al. KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res. 56(21):1996;4876-4880.
38. Guo X.Z.et al. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatology. 28(6):1998;1481-1488.
39. Yu Y.et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res. 3(7):1997;1045-1049.
40. Adachi M.et al. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res. 56(8):1996;1751-1755.
41. Uchida S.et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 79(7-8):1999;1168-1173.
42. Geradts J.et al. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Am J Pathol. 154(6):1999;1665-1671.
43. Takaoka A.et al. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene. 16(11):1998;1443-1453.
44. Takaoka A.et al. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res. 89(4):1998;397-404.
45. Moreno J.G.et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 52(21):1992;6110-6112.
46. Katz A.E.et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 43(6):1994;765-775.
47. Ghossein R.A.et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma. Clinical implications J Clin Oncol. 13(5):1995;1195-1200.
48. Sokoloff M.H.et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging. A clinicopathological molecular analysis of 121 patients J Urol. 156(5):1996;1560-1566. [see comments].
49. Santanyana G. Flux and Constancy in Human Nature. 1905.
50. Welch D.R. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis. 15(3):1997;272-306.
51. Moore G.E., Sandberg A., Schubarg J.R. Clinical and experimental observations of the occurrence and fate of tumor cells in the blood stream. Ann Surg. 146:1957;580-587.
52. Moore G.E., Sandberg A.A., Watne A.L. The comparative size and structure of tumor cells and clumps in the blood and bone marrow, and tumor imprints. Cancer. 13:1959;111-117.
53. Koo J.et al. Recovery of malignant tumor cells from the right atrium during hepatic resection for hepatocellular carcinoma. Cancer. 52(10):1983;1952-1956.
54. Salsbury A.J. The significance of the circulating cancer cell. Cancer Treat Rev. 2(1):1975;55-72.
55. Sellwood R.A.et al. Factors affecting the finding of cancer cells in the blood. Br J Surg. 56(9):1969;649-652.
56. Feynman R. The meaning of it all; Thoughts of a citizen scientist. 1998;Addison-Wesley Publishing Company, Cambridge, MA.
57. Nelson P.S.et al. An expressed-sequence-tag database of the human prostate. Sequence analysis of 1168 cDNA clones Genomics. 47(1):1998;12-25.
58. Hawkins V.et al. Pedb. The prostate expression database Nucleic Acids Res. 27(1):1999;204-208.
59. Kendrew J. The Thread of Life. An Introduction to Molecular Biology:1996;Harvard University Press, Cambridge, MA.
60. Schrodinger E. What is life? The Physical Aspect of the Living Cell: With Mind and Matter: & autobiographical sketches:1992;Cambridge University Press, New York.
61. Coffey D.S. Self-organization, complexity and chaos. The new biology for medicine Nat Med. 4(8):1998;882-885. [see comments].
62. Schwab ED, Pienta KJ. Explaining aberrations of cell structure and cell signaling in cancer using complex adaptive systems. Adv Mol Cell Biol 1997;207-47.